Enzo Biochem Inc. Finalizes Merger, Shareholders to Receive $0.70 Per Share in Cash
Enzo Biochem Inc. has completed its merger, converting each share of its common stock into a cash payment of $0.70. The acquisition involved the cancellation or conversion of all outstanding warrants and certain restricted stock units into cash rights. This transaction was finalized according to the terms of the Merger Agreement, with related agreements available as filed exhibits.
Enzo Biochem Inc. has completed the acquisition of its assets, as detailed in a recent filing. According to the company’s announcement, each share of Enzo Biochem’s common stock was converted into the right to receive $0.70 in cash at the time of the merger’s effectiveness. Additionally, all outstanding company warrants and certain restricted stock units were canceled or converted into cash rights. The transaction was finalized under the terms set out in the Merger Agreement, and the related agreements are available as filed exhibits. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enzo Biochem Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-078736), on August 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
